Clinuvel Pharmaceutical Forecast, price target & analysts
Clinuvel Pharmaceutical Target price 2024 - Analyst rating & recommendation
Clinuvel Pharmaceutical Classifications & Recommendation:
Clinuvel Pharmaceutical Price Target
| Target Price | AUD30.00 |
| Price | AUD13.73 |
| Potential |
118.51%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Clinuvel Pharmaceutical 2025 .
The average Clinuvel Pharmaceutical target price is AUD30.00.
This is
118.51%
register free of charge
AUD48.00
249.60%
register free of charge
AUD17.00
23.82%
register free of charge
|
|
| A rating was issued by 7 analysts: 7 Analysts recommend Clinuvel Pharmaceutical to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Clinuvel Pharmaceutical stock has an average upside potential 2025 of
118.51%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Jun '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million AUD | 88.18 | 98.23 |
| 12.59% | 11.39% | |
| EBITDA Margin | 50.74% | 49.24% |
| 4.71% | 2.95% | |
| Net Margin | 40.89% | 38.49% |
| 3.14% | 5.87% |
6 Analysts have issued a sales forecast Clinuvel Pharmaceutical 2025 . The average Clinuvel Pharmaceutical sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Clinuvel Pharmaceutical EBITDA forecast 2025. The average Clinuvel Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Clinuvel Pharmaceutical Analysts have issued a net profit forecast 2025. The average Clinuvel Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Jun '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share AUD | 0.72 | 0.76 |
| 16.13% | 5.56% | |
| P/E | 18.19 | |
| EV/Sales | 5.13 |
3 Analysts have issued a Clinuvel Pharmaceutical forecast for earnings per share. The average Clinuvel Pharmaceutical <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Clinuvel Pharmaceutical stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Clinuvel Pharmaceutical...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
